Skip to main content

Table 2 Fitted vaccine RTS,S properties

From: The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models

Cohorts

Initial efficacy

Half-life (exponential decay)

6-12 week

62.7 %

1.12 years

cohort

(with 95 % CI 39.5-80.3 %)

(with 95 % CI 1-1.43 years)

5-17 month

79.2 %

1.12 years

cohort

(with 95 % CI 67.3-84.8 %)

(with 95 % CI 1-1.43 years)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us